R&D

Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap

Anyone shopping for some early- and mid-stage neurosciences programs should look over the menu of discontinued programs out from Pfizer $PFE this morning.

As the pharma giant already noted, it is getting rid of everything on the neurosciences side except its late-stage pain program allied with Eli Lilly. So the chopping block today includes a Phase I gamma secretes approach, PF-06648671, as well as a GABA-A receptor agonist for epilepsy and a dopamine 1 activator for cognitive disorders.

And that’s not all. There’s a Phase I myeloperoxidase inhibitor for NASH that didn’t make the cut and curiously an IDO1 inhibitor for cancer that will wrap up its presence in the pipeline.

The big setback for Pfizer was the failure of their PD-L1 checkpoint Bavencio for third line gastric cancer — which is being swept out into the scrap heap today.

That program isn’t going anywhere. But anyone interested in neurosciences should take a look at what Pfizer will likely hand over — cheap.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription


Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->